We are pleased to announce the appointment of Richard Grethe as a Non-Executive Director to CHASE.
Richard has a rich history and extensive experience in the UK life-sciences industry. He started his career as a Chartered Accountant at KPMG and has worked in Pharmaceuticals for 30 years at Wellcome PLC, Medeva, Celltech, and UCB.
In 2004, he was a founding member of Focus Pharma and sold it to trade in 2014. Since 2015, Richard has served as CFO and subsequently Non-Executive Director of the market-leading medical animation company Random42.
On joining CHASE Richard said:
I have arrived at CHASE having been involved in PE-backed Pharma businesses for nearly 20 years. The knowledge I have is wide, and Graham and the team are a real bunch of people I can get on with and help develop the business going forward. The CHASE team are trusted in the industry, hard-working and innovative in their approach, and adapt to a changing market effortlessly.
Graham Hawthorn, Managing Director of CHASE said:
We’re delighted that Richard has joined our team. His experience, both client and service side, will be invaluable as we continue to develop the CHASE offering.
Explore our latest thinking, event updates and industry insights to stay informed.
Kent and Medway has signed the first local variation of the PCN DES, worth £10 million a year. CHASE assesses what the framework still leaves unsettled.
From April 2027, NHS Carbon Reduction Plan rules demand full scope 3 emissions data. CHASE assesses what this means for pharma and medtech suppliers.
Yvette Cooper is the UK's new health secretary after a reshuffle that also reshaped the medtech brief. Here's what it means for pharma, medtech and NHS teams.
.svg)
